Administration of an antigen (Ag) per oral route leads to apoptosis of Ag-specific CD4 ؉ T cells and to development of Th2 cells expressing Fas ligand (FasL) in the liver. We determined whether presentation of an ingested Ag in the liver alone was enough to select these 
T ransplantation of an allogeneic liver sometimes requires little or no immunosuppressive therapy, and rejection of an organ transplanted together with the liver is often inhibited. 1, 2 Moreover, administration of an antigen (Ag) via the portal vein induces local as well as systemic tolerance to the Ag 3, 4 ; this phenomenon has been applied successfully to the treatment of insulindependent diabetes mellitus by transplanting islet cells via the portal vein. 5 This phenomenon, sometimes called portal vein tolerance, 6 may represent a physiologic response by the liver to bacterial and dietary Ags that are omnipresent in the gut and migrating to the liver via portal circulation. Consistent with this notion, portosystemic shunt in animals abrogates systemic tolerance to dietary Ags, indicating that the liver is indispensable in establishing oral as well as portal vein tolerance. 7 Recently, we found that oral administration of an Ag leads to development of tolerogenic CD4 ϩ T cells in the liver, which is achieved by both apoptosis and deviation to Th2 response by the Ag-specific CD4 ϩ T cells. 8 Thus, our study suggested that the activation and selection of CD4 ϩ T cells specific to a dietary Ag were operating in the liver and involved in the induction of portal vein tolerance just as antigenic activation followed by selection was the case in the thymus for the induction of systemic tolerance. 9 Therefore, our own study, together with those by others, argues for the presence of Ag-presenting mechanisms leading to tolerance in the liver. Indeed, liver dendritic cells (DCs) and liver sinusoidal endothelial cells (LSECs) can present Ags to CD4 ϩ T cells in an MHC class IIrestricted manner. 10, 11 In this study, we determined whether Ag-presenting cells (APCs) in the liver are required to achieve portal vein tolerance. We report that Ag presentation by hepatic CD11c ϩ cells of mice fed an Ag is sufficient to induce apoptosis of Ag-specific CD4 ϩ T cells and differentiation to Th2 cells, which may explain tolerogenic properties of the liver.
Materials and Methods
Animals and Protocol for Immunization. BALB/c mice were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Japan). DO11.10 mice with T cells bearing the transgenic T cell receptor that recognizes the 323-339 peptide fragment of ovalbumin (OVA) in the context of IA d 12 were crossed to Rag 2 Ϫ/Ϫ mice. These mice were housed under specific pathogen-free conditions in the Animal Facility of Kyoto University. Eightweek old male BALB/c mice were fed 100 mg of OVA (Sigma Chemical Co., St. Louis, MO) or phosphate-buffered saline (PBS) every other day for a total of 5 times. In some experiments, BALB/c mice were treated with intravenous injection of 1 mg of OVA or PBS every other day for a total of 5 times. All animal experiments were performed in accordance with institutional guidelines, and ethical permission for this study was granted by the review board of Kyoto University.
Immunohistochemistry. BALB/c mice were administered of 100 mg OVA-fluorescein isothiocyanate (FITC) (Molecular Probes, Eugene, OR) orally and killed at the indicated time points. Eight-m liver sections were fixed in cold acetone and incubated with biotinylated antimouse IA d (Pharmingen, San Diego, CA) followed by the incubation with streptavidin-Rhodamine (Southern Biotechnology, Birmingham, AL) using TSA-Biotin kit (NEN, Boston, MA) as previously described. 13 Slides were analyzed by confocal microscopy with Zeiss Axioplan/BioRad MRC 1024 confocal laser microscope (Zeiss, Obenkochen, Baden-Wuerttemberg, Germany).
Stimulation of Naive Ag-Specific CD4 ؉ T Cells by CD11c ؉ Cells From Mice Fed an Ag. Lymphocytes were prepared from the spleen, draining lymph nodes (dLNs), and Peyer's patches as previously described. 14, 15 Intrahepatic lymphocytes and low density cells (LDCs) were prepared as described previously. 8, 16 Splenic and hepatic CD11c ϩ cells were enriched from the suspension of LDCs by positive selection using autoMACS (Miltenyi Biotec, Bergisch Gladback, Germany). Naive OVA-specific CD4 ϩ T cells were prepared from the spleen of Rag 2 Ϫ/ϪDO11.10 mice by positive selection using autoMACS (purity; Ͼ95%). Purified CD4 ϩ T cells (5 ϫ 10 4 /well) were stimulated for 3 days in the culture containing 1 g/mL of OVA-peptide presented by irradiated hepatic or splenic CD11c ϩ cells (1.25 ϫ 10 4 /well) from BALB/c mice fed OVA or PBS. Culture supernatants were collected at 48 hours for interferon gamma (IFN-␥) and interleukin (IL)-2 and at 72 hours for IL-4, IL-10, and transforming growth factor ␤ 1 (TGF-␤ 1 ).
Stimulation of CD11c ؉ Cells by CD40 Ligation. LDCs were prepared from the spleen, Peyer's patches, and the liver of BALB/c mice fed OVA or PBS. These cells were separated further into CD11c ϩ cells and CD11c Ϫ cells by autoMACS (purity; CD11c ϩ Ͼ90%, CD11c Ϫ Ͼ85%). These cells (1.0 ϫ 10 5 /well) were incubated with agonistic anti-mouse CD40 (3/23, 25 g/mL, Pharmingen) or control rat immunoglobulin G 2a (Pharmingen) for 48 hours in U-bottom 96-well culture plates. Culture supernatants were analyzed for the level of IL-10, IL-12 p70, IL-18, and TGF-␤ 1 .
In Vitro Apoptosis Assay. OVA-specific naive CD4 ϩ T cells were stimulated by OVA-peptide presented by hepatic CD11c ϩ cells from BALB/c mice fed OVA or PBS. To this culture, we added neutralizing antibodies to murine IL-12 (10 g/mL, C17.8, Pharmingen) and Fas ligand (FasL; 10 g/mL, MFL4) 17 or murine rIL-12 (10 ng/mL; PeproTech, London, England). As controls, rat immunoglobulin G 2a and hamster immunoglobulin G (ICN pharmaceuticals, Inc., Aurora, OH) were used.
Oral Immunization to Mice That Received OVASpecific CD4 ؉ T Cells. We transferred OVA-specific CD4 ϩ T cells from DO11.10 mice into naive BALB/c mice (containing 2.5 ϫ 10 6 CD4 ϩ KJ1-26 ϩ T cells/ mouse) as previously described. 18 Three days after the transfer, the recipient mice were fed PBS or 100 mg of OVA every other day for a total of 5 times and treated intravenously with PBS or rIL-12 (300 ng/mouse, PeproTech) every 3 days. Mice were killed at the indicated time points.
Cotransfer of Hepatic CD11c ؉ Cells and Splenic OVA-Specific CD4 ؉ T Cells to the Recipient Mice. To determine in vivo functions of CD11c ϩ cells, CD11c ϩ cells and OVA-specific CD4 ϩ T cells were co-transferred to BALB/c recipient mice that were subsequently immunized with OVA. Six-week old naive male BALB/c mice were coinjected intravenously with 5 ϫ 10 5 CD11c ϩ cells purified from the spleen and the liver of BALB/c mice fed OVA or PBS for a total of 5 times and with 2.5 ϫ 10 6 CD4 ϩ KJ1-26 ϩ T cells purified from the spleen of DO11.10 mice (day 1). In some experiments, CD11c ϩ cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR). The next day after the transfer (day 0), the recipient mice were subcutaneously immunized with 100 g of OVA in complete Freund's adjuvant (Life Technologies). In some experiments, the recipient mice were treated with intravenous injection of rIL-12 (500 ng/mouse) or PBS every 3 days from the first day of subcutaneous immunization. At the indicated time points, mononuclear cells were prepared from the dLNs. OVA-peptide (1 g/mL) was used to stimulate dLN cells (3 ϫ 10 5 /well) for 72 hours, and incorporated thymidine was determined as described previously. 8 Culture supernatants were collected at 48 hours for IFN-␥ and at 72 hours for IL-4.
Cytokine Analysis. The concentrations of IL-2 and IL-4 were determined with CTLL-2 and CT.4S cell lines, respectively, 19,20 as previously described. 8 The concentrations of IL-10 and IFN-␥ were measured by sandwich enzyme-linked immunosorbent assay as described previously. 8 TGF-␤ 1 (Promega, Madison, WI), IL-12 p70 (Pharmingen), and IL-18 (Pharmingen) were measured using commercial enzyme-linked immunosorbent assay kits.
Monoclonal Antibodies and Flow Cytometry. The following monoclonal antibodies were purchased from Pharmingen: anti-CD4, CD8␣, CD11b, CD80, CD86, CD11c, Fas, FasL, IA d , CD25, and CD122. Anti-CD40 and F4/80 were purchased from Serotec (Oxford, England). KJ1-26 recognizing transgenic T cell receptor specific to OVA was purchased from Caltag (San Francisco, CA). These antibodies were coupled directly to FITC, phycoerythrin, or biotin, in which case staining was revealed by streptavidin-FITC (Pharmingen), streptavidinphycoerythrin (Pharmingen), or streptavidin-RED670 (Life Technologies). Cells were preincubated with saturating doses of 2.4G2 to prevent antibody binding to Fc receptor. Apoptotic cells were detected using an Annexin V apoptosis detection kit (Pharmingen). Surface immunofluorescence was assessed as described previously 21 using a flow cytometer (Epics XL, Coulter Electronics, Miami, FL). Dead cells were excluded by propidium iodide (PI) staining.
Statistical Analysis. Student's t test was used to evaluate the significance of the differences. Statistical analysis was performed with the Stat View v.4.5 program (Abacus Concepts, Berkeley, CA).
Results
Localization of an Ag Fed in the Liver. In our recent study, we showed that feeding of OVA leads to activation of OVA-specific CD4 ϩ T cells in the liver. 8 To confirm that the OVA ingested was absorbed and taken up by hepatic APCs, we fed mice FITC-labeled OVA and assessed its localization in the liver. As shown in Fig. 1 , after 3 and 24 hours of feeding, FITC-labeled OVA accumulated in the periportal and parenchymal area of the liver and was colocalized with IA dϩ cells. Thus, a part of OVA administered per oral route is taken up by class II ϩ cells in the liver, suggesting that presentation of an ingested Ag can occur in the liver.
Ag Presentation by Hepatic CD11c ؉ Cells Generates Th2 Cells. Since Ag presentation can occur in the liver and OVA-specific Th2 cells emerge on feeding of OVA, 8 we assessed a requirement of hepatic APCs for this Th2 cell development. To do this, we studied the property of hepatic CD11c ϩ cells in mice fed OVA, because CD11c ϩ cells are professional APCs and most of class II ϩ cells also were positive to anti-CD11c staining (73.5 Ϯ 6.7 % and 78.1 Ϯ 6.0 % of IA dϩ cells were positive for anti-CD11c staining by flow-cytometry in the liver of mice fed PBS and OVA, respectively). Flow-cytometric analysis revealed that 65.1 Ϯ 10.2, 52.9 Ϯ 9.3, and 76.2 Ϯ 4.3 % of hepatic CD11c ϩ cells were positive for anti-CD40, CD80, and CD86 staining, respectively. Only 6.1 Ϯ 2.2 % of hepatic CD11c ϩ cells was positive to anti-F4/80, a marker specific to Kupffer cells. Naive OVA-specific CD4 ϩ T cells were stimulated with these CD11c ϩ cells pulsed with OVA-peptide to assess whether the CD11c ϩ cells may direct Th differentiation. As shown in Fig. 2 , Ag presentation by hepatic CD11c ϩ cells of mice fed OVA suppressed IL-2 secretion and enhanced the secretion of IL-4 and IL-10 by CD4 ϩ T cells. In contrast, no significant changes in IL-4 or IL-10 secretion were seen in CD4 ϩ T cells stimulated with splenic CD11c ϩ cells, although there was a decrease of IL-2 secretion. No significant alteration was seen in the secretion of IFN-␥ and TGF-␤ 1 by CD4 ϩ T cells stimulated with CD11c ϩ cells from either organ. Because naive splenic CD4 ϩ T cells were utilized in this study, the result indicated that OVA-presentation by the hepatic CD11c ϩ cells is enough to achieve Th2 differentiation.
IL-12 and IL-18 Secretion by Hepatic CD11c ؉ Cells. Because cytokines produced by APCs at the timing of antigenic activation determine subsequent Th-differentiation of CD4 ϩ T cells, we assessed cytokines produced by CD11c ϩ cells. Thus, hepatic or splenic CD11c ϩ cells from mice fed OVA were stimulated with agonistic anti-CD40 monoclonal antibodies as a surrogate stimulus provided by cognate T cells. As shown in Fig. 3A and B, anti-CD40 stimulation significantly reduced the production of IL-12 and increased IL-18 secretion by hepatic CD11c ϩ cells from mice fed OVA, whereas such significant alterations were not seen in splenic CD11c ϩ cells. To determine whether these changes were observed only in CD11c ϩ cells, we assessed production of cytokines by LDCs (containing both CD11c ϩ and CD11c Ϫ cells) or purified CD11c Ϫ cells. Similarly, IL-12 and IL-18 secretions by hepatic LDCs were significantly altered in the mice fed OVA (data not shown). However, IL-12 and IL-18 secretion by hepatic CD11c Ϫ LDCs remained unchanged (data not shown).
No changes were seen in the production of IL-10 or TGF-␤ 1 by hepatic CD11c ϩ or CD11c Ϫ LDCs from mice fed OVA (data not shown). Thus, these data altogether suggested that, in mice fed OVA, hepatic CD11c ϩ cells produce less IL-12 and more IL-18 on cognate interaction with CD4 ϩ T cells compared with those produced by splenic CD11c ϩ cells. This alteration in IL-12/IL-18 production by hepatic CD11c ϩ cells did not depend on the route of Ag administration because intravenous injection of OVA also led to decrease of IL-12 production and increase of IL-18 production by hepatic CD11c ϩ cells (Fig. 3C and D) IL-12 Prevents Apoptosis of CD4 ؉ T Cells Stimulated With Hepatic APCs. Because Th2 development in the liver of mice fed an Ag was associated with apoptosis of Ag-activated CD4 ϩ T cells, 8 we studied the possibility that Ag-presentation by hepatic CD11c ϩ cells may cause cell death. This was the case because Ag-presentation by hepatic CD11c ϩ cells of mice fed OVA led to an increase of the percentage of Annexin V ϩ PI ϩ cells in KJ1-26 ϩ T cells, indicating an occurrence of apoptosis of OVA-specific CD4 ϩ T cells (Fig. 4A) . This apoptosis was prevented by anti-FasL treatment. Interestingly, addition of IL-12 to this culture also prevented apoptosis and, to the contrary, anti-IL-12 treatment increased apoptosis. These effects by IL-12 and anti-IL-12 treatment were not mediated by Fas or FasL expression in KJ1-26 ϩ T cells (Fig.  4B) . We next studied the possibility that IL-12/anti-IL-12 treatment may directly regulate cell survival signals in the Ag-activated CD4 ϩ T cells. Indeed, this was the case because IL-12 treatment augmented CD122 (IL-2R␤) expression whereas anti-IL-12 treatment suppressed it. CD25 (IL-2R␣) expression was augmented by antigenic stimulation and was not affected by either treatment. Thus, overall effect of IL-12 on KJ1-26 ϩ T cells activated by hepatic CD11c ϩ cells was an increase in expression of functional IL-2R. Moreover, IL-12 treatment increased IL-2 and IFN-␥ secretion and decreased IL-4 secretion by CD4 ϩ KJ1-26 ϩ T cells stimulated by hepatic CD11c ϩ cells from mice fed OVA (Fig. 4C) . Taken together, a decrease of IL-12 secretion by hepatic CD11c ϩ cells can abrogate the cell survival signal mediated by autocrine loop of IL-2/IL-2R of KJ1-26 ϩ cells, which was independent on the mechanism mediated by Fas/FasL interaction between activated KJ1-26 ϩ T cells. 3 times led to clonal expansion of CD4 ϩ KJ1-26 ϩ T cells in the liver of the recipient mice, which was followed by clonal deletion of CD4 ϩ KJ1-26 ϩ T cells after the fifth feeding (Fig. 5A, open symbol) . To the contrary, the decrease of CD4 ϩ KJ1-26 ϩ T cells was prevented significantly in the recipient mice treated with IL-12 (Fig. 5A,  closed symbol) . This prevention effect by IL-12 was not seen in the spleen of the recipient mice, in which significant level of apoptosis did not occur by feeding of OVA. The effect of IL-12 on the cell death was confirmed by the analysis of Annexin V expression in hepatic KJ1-26 ϩ T cells. Thus, in the mice fed OVA for a total of 3 or 5 times and treated with IL-12, an increase of the percentage of Annexin V ϩ cells in hepatic KJ1-26 ϩ T cells was suppressed (Fig. 5B) . This suppression effect of IL-12 required antigenic cell activation because systemic administration of IL-12 alone did not inhibit apoptosis of OVA-specific CD4 ϩ T cells in the liver of PBS-fed mice that were transferred of those cells (data not shown). Taken together, these data indicated that IL-12 prevented the cell death of CD4 ϩ KJ1-26 ϩ T cells in the liver of mice fed OVA.
IL-12 Prevents
Adoptive Transfer of Hepatic CD11c ؉ Cells Generates Systemic Th2 Response in the Recipient Mice. To confirm that hepatic CD11c ϩ cells can direct Th differentiation and induce apoptosis in vivo, we did a cell transfer experiment. Donor BALB/c mice were administered OVA or PBS orally, and hepatic or splenic CD11c ϩ cells were prepared. We then cotransferred CD11c ϩ cells and DO11.10 T cells into naive BALB/c recipients, which were subsequently immunized with OVA/complete Freund's adjuvant subcutaneously. As shown in Fig. 6A , both hepatic and splenic CD11c ϩ cells labeled with CFSE equally migrated to dLNs of the recipient mice 3 days after OVA challenge (Fig. 6A) . The time course study indicated that transferred CD4 ϩ KJ1-26 ϩ T cells proliferated in dLNs in all groups of the recipient mice 3 days after OVA-challenge. Eight days after the subcutaneous challenge (day 8), percentage and total number of CD4 ϩ KJ1-26 ϩ T cells were significantly decreased in the mice that received hepatic CD11c ϩ cells of mice fed OVA, whereas the decrease was very little in the other groups of mice ( Fig. 6B and C) . The decrease of CD4 ϩ KJ1-26 ϩ T cell population was associated with an increase of the percentage of Annexin V ϩ cells (Fig. 6C) and Fas ϩ and/or FasL ϩ cells (data not shown) in the same population. On day 8, a significant decrease in both T cell proliferation and IFN-␥ secretion was seen only in the mice transferred with hepatic CD11c ϩ cells of mice fed OVA, which was associated with a significant increase in IL-4 secretion (Fig. 6D) . Finally, these effects by hepatic CD11c ϩ cells on apoptosis (Fig. 7A) and on cytokine production by CD4 ϩ KJ1-26 ϩ T cells (Fig. 7B) in the recipient mice were abolished by IL-12 injection to recipient mice. Thus, these data altogether indicated that concomitant deletion of OVA-specific CD4 ϩ T cells and the development of Th2 cells in the liver were achieved in part by down-regulation of IL-12 secretion by hepatic CD11c ϩ cells of the mice fed OVA.
Discussion
The liver is an immunologically privileged organ with the capacity to tolerate Ags migrating via the portal vein. The mechanism inducing this type of tolerance is not fully understood. We recently showed that oral administration of an Ag generates regulatory FasL ϩ Th2 cells in the liver, which suppress several immune responses both in vitro and in vivo. 8 The generation of those regulatory T cells in the liver may help maintain immunological homeostasis in the liver, which is perfused by the portal blood containing immunogenic macromolecules derived from ingested foods or intestinal microfloras. In this article, we found that tolerogenic responses to an ingested Ag were not caused by the innate property of hepatic CD4 ϩ T cells but by that of hepatic CD11c ϩ cells presenting Ags. Thus, hepatic CD11c ϩ cells capture Ags in the portal Fig. 6 . In vivo selection of OVA-specific Th2 cells via apoptosis in the recipient mice of hepatic CD11c ϩ cells. BALB/c mice were orally immunized as described in Fig. 2 and CD11c ϩ cells in the liver or spleen were purified. These CD11c ϩ cells (5 ϫ 10 5 /one mouse) and splenic CD4 ϩ KJ1-26 ϩ T cells (2.5 ϫ 10 6 /one mouse) from naive DO11.10 mice were cotransferred intravenously into recipient BALB/c mice (day -1). On day 0, recipient mice were subcutaneously immunized with 100 g of OVA/complete Freund's adjuvant. vein and drive Ag-specific CD4 ϩ T cells to Fas-mediated apoptosis as well as to Th2 differentiation.
Several issues are to be considered in regard to the mechanism of how the feeding of an Ag leads to development of the regulatory CD4 ϩ T cells in the liver. First, to elaborate on hepatic APCs, as a candidate of hepatic APCs, Knolle et al. showed that LSECs can present Ags and regulate cytokine secretion by CD4 ϩ T cells. 11 Another investigator showed that the liver possesses DCs, which generate Th2 cells in LNs of the mice on transfer. 10 We show here that the FITC-labeled OVA administered was colocalized with class II ϩ cells in the areas rich in DCs (periportal region) and in LSECs (parenchymal region), indicating that a part of OVA was captured by APCs in an immunogenic form. Phenotypic analysis shows that hepatic class II ϩ cells express CD11c and costimulation molecules. Because both LSECs and DCs are positive to these cell-surface markers, we do not preclude the possibility that our CD11c ϩ cell preparation included LSECs in addition to DCs. Most of Kupffer cells were eliminated because there were very few F4-80 ϩ cells.
Second, we question the mechanism of how hepatic CD11c ϩ cells direct naive Ag-specific CD4 ϩ T cells to Th2 differentiation. Apparently, a profile of cytokines produced by hepatic CD11c ϩ cells may explain a bias to Th2 cell development. Thus, oral administration of OVA down-regulated IL-12 secretion and up-regulated IL-18 secretion by hepatic CD11c ϩ cells. In concert with IL-12, IL-18 is originally reported to generate Th1 cells. 22, 23 However, recent reports indicated that IL-18 also could generate Th2 response in the absence of IL-12 or in the presence of IL-4. 24, 25 Our data were compatible to the latter idea in that the appearance of Th2 cells after feeding of OVA was not only caused by the decrease in IL-12 secretion but also by the increase in IL-18 secretion by hepatic CD11c ϩ cells. Moreover, we confirmed that addition of IL-18 to the culture containing OVA-specific CD4 ϩ T cells and splenic CD11c ϩ cells pulsed with OVA-peptide leads to a significant increase of IL-4 production as well as a decrease of IFN-␥ production in the presence of anti-IL-12 monoclonal antibodies (T. Watanabe and Y. Wakatsuki, unpublished observations). In this regard, we do not deny the possibility that the genetic background of the mice used in this study might have affected this deviation to Th2 response.
Third, there is an issue concerning the mechanism of how OVA administered to the mice deletes CD4 ϩ KJ1-26 ϩ T cells in the liver 8 . IL-12 is found to regulate expression of functional IL-2R␤, which is critical for the Agactivated CD4 ϩ T cells to survive in the environment in which availability of IL-2 is limited. In addition to the effect on IL-2R-mediated signal, IL-12 prevents Fas-mediated cell death of activated T cells by inhibiting caspase-3 enzyme activity. 26 Considering the points alluded above, we propose the mechanism of how OVA administered selects Th2 cells in the liver as follows: A part of OVA ingested is carried by portal blood flow to the liver in an immunogenic form and then captured by class-II ϩ /CD11c ϩ cells in the liver. OVA presented by APCs activates hepatic OVA-specific CD4 ϩ T cells, which is followed by up-regulation of FasL expression. 8 Because hepatic CD4 ϩ T cells constitutively express Fas, 8 FasL expression can lead to clonal deletion of both Th1 and Th2 cells by interaction between Ag-activated CD4 ϩ T cells. The increase of IL-18 by CD11c ϩ cells also promotes Fas-mediated apoptosis because IL-18 up-regulates FasL expression in T cells. 27 Moreover, at this point, the decrease of IL-12 secretion, which is a conspicuous property of hepatic CD11c ϩ cells, can play roles of two kinds. First, as alluded to above, a decrease of IL-12 secretion not only enhances cell-death signal mediated by Fas but also decreases survival signal by downregulating IL-2R expression of Ag-specific CD4 ϩ T cells. Second, together with an increase of IL-18 secretion, a decrease of IL-12 secretion drives CD4 ϩ T cells to Th2 differentiation. Resulting Th2 cells produce a large amount of IL-4, which renders those IL-4-secreting cells resistant to apoptosis by increasing Bcl2 and Bclxl expression. 28, 29 Thus, overall effects of down-regulation of IL-12 secretion by CD11c ϩ cells can result in enhanced cell death of OVA-specific Th1 cells by Fas-mediated apoptosis. This conclusion is supported by the results of the adoptive transfer of CD11c ϩ cells and in vivo administration of rIL-12.
These findings can explain the results of our recent study that feeding of OVA selects OVA-specific FasL ϩ Th2 cells in the liver via Fas/FasL-mediated apoptosis. 8 Furthermore, the data presented in this article indicated that hepatic CD11c ϩ cells from mice fed OVA are sufficient for the Th2 development because the former cells drive splenic CD4 ϩ T cells to Th2 differentiation. One of the questions that remains to be answered is how feeding of OVA down-regulates IL-12 secretion and upregulates IL-18 secretion by hepatic CD11c ϩ cells, which is not seen in splenic or Peyer's patches CD11c ϩ cells (data not shown). In this regard, we found that constituents of CD11c ϩ cells in these organs are different. CD8␣ ϩ CD11c ϩ DCs enhance Th1 differentiation by producing a large amount of IL-12. 30 The percentage of CD8␣ ϩ cells in CD11c ϩ population in the liver of mice fed OVA is 14.9 Ϯ 6.2%, whereas those in the spleen and Peyer's patches is 26.9 Ϯ 11.2% and 25.5 Ϯ 8.0%, respectively. Thus, a significant decrease of CD8␣ ϩ CD11c ϩ cells may affect Th regulation by limited production of IL-12 of hepatic CD11c ϩ cells.
In summary, we showed that hepatic CD11c ϩ cells promote both clonal deletion and differentiation to FasL ϩ Th2 cells of CD4 ϩ T cells specific to an Ag administered orally, which is mediated in part by down-regulation of IL-12 secretion.
